Abs tract
The ph en omenon of pe rfo r m ance a nxiety (or "s tage fri ght ") has been a pprec ia ted for man y years. Th e sym pto ms a re not ed imm ed iat ely prior to a nd du ri ng va rious performance tasks , e.g., music, public speaking, a t hletics, and t est tak ing, a nd a re referabl e to th e sympath etic nervous sys te m . Althou gh no standard seri es of sym pto ms spec ific to this cond itio n has been develop ed , tachyca rd ia / pa lpita t io ns, trem or, a nd swe a t ing a re cite d most common ly, wit h various other sym p to ms list ed less co ns iste n t ly (1-16, T abl e I).
A s mall, manageable a mo u nt of a u to no m ic aro usal may we ll be adap t ive by se rving to incr ease th e performer's e ne rgy . For many o t her perform ers, however , th ese sympt oms are excessive a nd coun te r prod uct ive. Wit ness t he viol in ist or arch er with excessive tremor, th e trumpet er with dry mouth a nd short ness of br eath , or th e ac to r with excessive swea ting. This paper will exa mine th e eva lua t ion and m a nagem ent of performance a nxie ty sym ptoms.
DESCRIPTI O N AND DIFFERENfIAL DIAGNO SIS
Perform an ce anxiety is classifi ed in DSM-III-R as soc ia l ph obia (300 .23) ( 17) . These crite ria includ e: a persist ent fear of situa tions in wh ich th e person is expose d to sc ru t iny by o t he rs, a nd fears th at he / sh e may act in a hu m ilia t ing or e m ba r rass ing m ann er; expos u re to th e st im ulus provok es a n anxie ty response; th e phobic sit ua t ion is avo ide d or e nd u re d with grea t a nxie ty; a nd th e avo ida nt be havior int erferes with occ upa t iona l functi oning. DSM-III-R di stingui sh es bet ween t hos e person s with "ge ne ra lized" socia l phobia from thos e with " d isc re te" soc ia l ph ob ia whic h is limit ed to performance situations by th e cavea t that th e ge ne ralized type desc rib es those persons for whom th e phobia sit uatio n includes most soc ia l sit ua t ions. A st udy by H eimberg, H op e, Dod ge, a nd Beck er ( 18) co m pared a group of ge ne ra lized soc ial ph obics to a group who were ph obi c for public speaking only. They found t he ge ne ra lized soc ial ph obi cs to be lower-functi oning, a nd to have more severe ph obi c sym ptoms th an the public speaking phobics. The public speaking phobi cs wer e fou nd to hav e a noticeabl y gr eater incr ease in heart rat e in resp on se to a performance challe nge , as well as ove re stim a ting th e visibi lity of t he ir anxiety symptoms a nd unde res timating th e qu ality of thei r pe rforman ce whil e bein g obs erved.
Turne r a nd Beid el ( 19) st udie d a population of socially anxious person s who were as ked to give a speech. They found a sign ificant inc rease in blood pr essure du ring th e pe r for mance task for a subgroup d escribed with " high ph ysiologica l react ivity. " Their st udy did no t use DSM-III cri teria for social phobia, and th e specific symptoms of pe rformance a nxie ty vs. ge ne ra lize d socia l ph obia were not addressed.
An important distincti on m ust be m ad e bet wee n social phobia a nd pani c disorder. Althou gh th e ph ysical a nd cog nitive sym p to ms of t he two cond itions show co nside ra ble overlap, th e panic disorder pat ient experie nces symp tom attacks as u nexp ect ed a nd not tri gge red by sit ua tions in whi ch th e perso n is the focus of a tte n tion by others (17) . When th e pani c di sord er pat ien t develops phobic avoidance of soci a l sit ua tions, it is a fter th e onse t of panic d isord er and du e to fear of having a panic a ttack (ofte n in a non social sit ua tio n) , while t he soc ia l phobic is a fra id of ac ting in an em ba rrassing or humili ating way (20) . Th e di st inct ion between socia l ph obia and pa nic disord e r has both di agn ostic a nd t he ra peutic importance, as treatment wit h tri cyclic a n tide p ressants is recom m ended for pan ic disord er, but is gen erall y ine ffec tive for soc ia l ph obi a (2 1). T o illus t ra te th is poin t, Pohl , Balon and Yeragani (22) rep orted a case of a mu sician who first develop ed pan ic a ttacks in a vari et y of sit ua tions . Eve n t ua lly, th e sym ptoms of palpitation s, swea ting, chest tightness, trembling, feelings of panic and fears of "going crazy" occ urred only with musical perform ance. H e res po nde d bri efly to prop ran olol, but eve n t ua lly was su ccessfull y treate d wit h imprimine. Becau se hi s init ial sym ptoms were spon taneous, thi s patien t is mo re acc ura te ly d escrib ed as havin g panic disord e r ra t her t ha n socia l phobia.
It is pos t ula te d th a t patients wit h soc ia l ph ob ia lim ited to performance sit uations a re u nu su all y respo nsive to th e peripheral somatic cues that result fr om ad re nergic ac tivation (2 1). There is some evide nce that such patients show a mor e d ra m at ic ca rdiovascula r resp on se to stressful performance stimu li ( 18) . The patient noti ces th e so ma tic sym pto ms (which nearly uniformly include tachyca rd ia, sweating, a nd trem or) a nd th en d evelop s a cog nitive percept th at ot hers will be particul arl y perceptive of th es e somatic sym p toms (18, 21) . This results in a vicious cycle wherein t he somatic sym ptoms lead to th e hypersen sitive cog nitions, lead ing to gr ea ter pe ripheral sym ptoms in a positive fee dbac k loop . This prop osed mechanism is in con t rast to th e ce n t rally driven mech anism felt to be responsible for pani c dis order. Leib owit z, Gorm an , Fyer a nd Klein not ed th at DSM-III social phobia patients had a subs ta n tia lly lowe r incid en ce of lact a te-indu ced pa nic symptoms th an did patie nt s suffe ring fro m panic disorder with agorapho bia, furt her supporting a neuroch emi cal differen ce between th ese two conditions (2 1).
Social phobia mu st a lso be disti ngui sh ed fro m avo idan t personality disorde r, whi ch represents a more lon g-st anding patt ern of soc ia l avo idance with less lik elihood of dis cr e t e episode s of ph ysical symp to ms . Pati ents wit h socia l ph obi a a re a lso pron e to a ffec tive illn ess and subst ance a buse , whi ch m ay be att empts to manage a nxie ty sympt oms (17) . Agras ( 15) not ed a sig nifica n t incid ence of com ple te avoida nce of th e phobic sit ua t ion , occupational cha nge, ami a nt icipa tory lise of alcohol in pati ents with public spe a king or mu sical pe rformance forms of soc ia l phobia.
PERFORM ANCE ANXI ETY IN PERFORIvIER GRO UPS
The fr equ en cy of intrusive perform an ce anxi et y eve n a mo ng seaso ned performe rs is sur p rising ly high. Performan ce a nxiety does no t necessa rily decr ease with e it he r increasin g musical pr oficien cy or perfor mance ex pe rience . Among well-known performers, Arthur Ruben st ein, Pablo Casals, an d Carly Simon a re said to have su ffere d from sig nifica n t performance a nx ie ty (23) . W esn er, Noyes , and Davis ( 10), in a survey of universit y music students a nd faculty, found th a t 16% of t he respondents felt th at th eir performance was m ark edl y impaired by t heir anx iety sympt om s, with poor co nce nt ra tion, rapid hea rtbeat , t re mo r, sweati ng and d ry mouth th e mo st co m mo nly rep ort ed perform an ce a nxie ty sym pto ms. Aud it ion s a nd solo performances (whe re in th e player is th e mo st exposed to the list e ne r's scrutiny) were ci te d as being "quite a bit" or "ext re me ly" anxi et y pr ovoking by a majority of th e resp ondents. The a u t ho rs a lso ask ed a bo u t other a nx ie ty symptoms including panic a ttacks a nd report ed th at 27% a nd 34% of th ei r sa mple claimed to be " ne rvo us pe rso ns" a nd to have had panic a ttacks, resp ectively. Of so m e not e is th at th eir qu esti onn aire did not defin e th ese terms fu r t her. Th e st udy showed very littl e use of a lcohol or drugs of a buse, while 4% of th e " im pa ire d " g ro up ad m itted to t he us e of pr escription m edications to cont ro l perform an ce a nx ie ty sym ptoms; beta-blocking age n ts were no t specifica lly qu estion ed fo r. Thou gh specific psychological psych othera pe u tic t echniqu es we re no t det a iled , ove r 50% of t he responde nts re por ted th eir use for th e managem ent of performan ce a nx iety.
Fishbein a nd Middlest adt (24 ) com ple te d a m aj or survey of over 2,000 professiona l mu sicians and found that 24% of th e resp ond ents report ed "s ta ge fright " as a sig nifica n t m edi cal pr obl em ; it wa s (a long with eye strain) th ei r most rep ort ed m edi cal co m pla in t. H owever, th e a u t hors did not define " sta ge frig ht" in terms of dis cret e ph ysical and psych ologi cal sym pto ms . They also not ed "acu t e anxiet y" as being report ed as a m edi cal probl em by 13% of th ei r resp ond e nt s. Pe r ha ps som e of this latt er g ro up had panic di sorder sym ptoms not temporall y-connected to perform an ce. Other psych ologic sym p to ms cite d by t he resp ondents were depression in 17%, slee p di sturban ces in 14%, a nd co nce rn ove r alcoho l co nsu m pt io n in 20%. Twenty-seven percent of th e respondents had used bet a-adren ergic block ing age nts (70 % of th ese were " non-pre scribe d occasional " us ers). O ccasion al use of betablo ck ers was most fr equ ent before auditions, solo recit al s, or difficul t or chestrat al performances. The vas t majority of those mu sicians wh o used beta-blockers on suc h a n occasio na l basis report ed success in stage fri ght sym ptom con t rol. Twenty-five percent of th e stage fr igh t suffere rs had resor te d to psych ological co unseling (tec h-niqu e un sp ecified ) for sym p to m re lie f, wit h 60% re po r ti ng s ucc ess. It has been cla im ed th at conflicts ove r ca ree r cho ice a nd d om esti c tu rm oil may be somewha t r esp on sible for the ex pe r ie nce of perform ance a n xie ty in th e m usicia n (25) .
V a rious a t hle t ic eve n ts which requ ir e fine m o tor co ntro l can be adversely a ffected by the ph ysical symptoms of perform ance a nx ie ty . For example, the rifl e shooter o r a rc he r ca n be rend e red un st ead y by palpitat ion s or tremor. The bowler, billiards pl ayer, or go lfer will be ill-served by ei t her sweaty pal m s or hand tremor. At a m ore cog nit ive level , focu sing on ot he rs' abili ty to see t he signs of performance a nx ie ty ca n serve to di st r act the co m pe t ito r a nd ke ep him from concentrating on his a t hle t ic skill (26) .
Actors a nd public speake rs ca n be a ffec te d by perform ance anxiety symptoms as well. It is diffi cult to m aintain concen t ra t ion on one 's speaking performan ce in th e face of palpit a ti on s, sweat ing, tremor or the ot he r sym p to ms of performance anxi et y. Also troubl esom e t o th e speake r a re dry m outh, vocal t remor, and shortn ess of breath .
BETA-ADRE NER GIC BLO CKING AGENT S-RATI O NALE FO R T REATMENT
Bet a-adrenergic blo cking agen ts a re thought to ac t per iphe rall y to block th e somat ic co m po ne n ts of th e anxi et y sta te . These sympto m s incl ud e tachycardia / palpi t ation s, trem or, a nd swea t ing, as well as vario us ot her symptoms ( Table I) . By block ade of the periph eral manifest a ti on s of a nx iety, th e pa ti en t perce ives les s a nxie ty, thu s blunting th e positive feedback loop where in the pe rception of somatic a nx ie ty sym p to ms le ad s to a nx io us thou ghts whi ch leads to more somat ic symptoms. It has lon g been a p p recia te d that sym pat he t ic ne rvou s system di sch a rge is associat ed wi th suc h sym p to ms ; beta-adren ergic block ad e is thus a t rea t m e nt consist ent with ph ysiol ogy.
It has ge ne rally been sho wn that the ac tio n of bet a-block e rs in reduci ng anxi et y sym p to ms is ba sed on th eir periph eral ac t ions; bet a-bl ock in g agents kn ow n not to pen etrat e the blood-brain barri er may redu ce a nxie ty sym p to ms, a nd a nx iolysis has been not ed with beta-block er do ses too low to ac h ieve ce n t ral ph ysiologica l effects (27) . Furtherm ore, in a nxie ty sta tes, th e ac tion of beta-block e rs on periph eral m anifestation s are more clearly redu ced th an a re th e purely psychic m an ifesta t ions, a nd va ri ou s performance ac ts a re improved with just th e periph er al actions of bet a-block ers (11 ,13) .
A st udy by Mills, Dimsd al e, Zi egl er et a l. (28) found lymphocyt e beta-adren ergic receptor d ensity a nd sensitivity to corre la te with the ca rd iovascu la r response to a m en tal st ressor. Thi s is of int erest in that excess card iovascu lar reactivity may predict the lat er d evelopm ent of ca rdi ovascula r di seas e ; it is pl ausible that ex ces s card iovasc u lar r eactivity may co r re la te wit h the d egre e of performance anxi et y sym p to ms as well.
Fo st er, Evans a nd H ardca stl e (29) moni tor ed th e pu lse rates of surgeons whil e they perform ed op erations a nd whil e t hey a tte nde d out patien t clinics. A typical increa se in pulse to a m ean of 121 BPM was see n in th e surgeo ns while they were operating; 40 m g of oxpre no lol red uced th e d uring surgery pu lse of th e surgeons to a m ea n of 84 BPM. C h ro nic ad m inist ration of be ta-adren ergic blocking ag ents is associat ed with a n incr eas e in th e number of bet a-adren ergic recept or s; thus a brupt d iscontinuation of th ese age n ts ca n ca use a withdrawal synd ro m e. The wit hdrawal symptoms may includ e a nx ie ty, tremulou sn ess, sweat ing an d t ach yca rd ia (16) . The notable sim ilarity between th ese sym pto ms a nd t he sym ptoms of performance anx iet y m ak e th e " pe riphe ral so ma t ic cues " mod el of perform an ce a nx iety a nd it s m an agem ent by bet a-adren ergic blo ckad e all t he more plau sibl e .
STUDIES OF BETA-ADRENERGIC BLO C KAD E FO R PER FO RMANC E ANXI ETY AN D/O R SOCIAL PH OBIA (TA BLE 2)
H artley, U ngape n, Davi e a nd Spe nce r ( I) st udied public speakers who received eit he r 40 m g propranolol or placeb o six ty to nin ety minut es prior to giving a speech. In part of th eir study, " a nxious" group was se lect ed on the bas is of th eir high scores on a sca le of trait a nxie ty . Followi ng th e sp eech , th e subj ects complet ed a scal e ofstate a nxi e ty. Propranolol was associa te d wit h a sign ificant d ecrease in th e state a nxie ty tr olled port ed in nearl y half of subjects on pro pr an olol. <;; Siiton en ,Janne
Liebowitz, Gorman, Fyer, et a!' ( I I, 14)
Gorm an , Liebowitz, Fyer , et a!' Oxprenolol blocked ta chycardia , improved scor es in subgroup with high cardiovascular reactivit y. Ph en elzin e decr eased sympto ms of ge ne ralized social phobia; ate nolol was no bett er than placebo for generalized social phobia, but effect ive for discret e social ph obia . 50% of patients with " mar ked"
and 40% of patient s with " moderate" improvem ent in socia l ph obia self-ra t ings.
Co mme nts :
Subjects withou t high ca rdiovascu lar reactivity had wor se scores wit h oxpreno lo!' " Discre te" social ph obia simila r to performan ce anxi ety.
50% of pati ent s with social phobia in study had history of depression ; 50% had hist or y of a lcoho l abuse . Performan ce anxiety pati ent s not distinguished fro m th ose with ge ne ra lized socia l ph obia . scores, as well as a decr ease in th e observe r ratings for sig ns of a nxie ty. Of not e is t he fact th at th e obs erve r in strument was a n " a nxiousne ss" scal e of one to 20; it apparently did not add re ss individu al ph ysical sym p to ms of a nxi et y. When t he authors co m pa re d a g ro up of a nx ious subj ects (on th e basis of sta te a nd tra it a nx iety scales) to a non-anxiou s gro u p, it was found th at pr opran olol sig nifica n t ly reduced th e pul se rat e in both g ro u ps, whil e ob servers looking for pau ses, sta m me ring, giggling and tremor not ed less speech-rela te d a nxie ty be havi o r in th e anxious su bj ec ts following propran olol , but no effect of th e d ru g on th e non-anxious. This distinction impli es a neuroch emical differen ce between th e two g ro u ps. Some impa irm ent in recall of so me it ems by a nxious subj ects seen with pr opra nolol sugges ted a ce n t ra l effect of propranolol. j am es , Griffith , Pearson a nd Newbu ry (2) st udied st ring m us icians receiving 40 m g oxprenolol vs. placeb o. The subj ects played a solo piece befor e a n a ud ie nc e and co m ple te d rating sca les for a nx ie ty before a nd afte r t he pe rfor m a nce, as well as assessments of performance. Blood pressure and pul se were mo nitored , a nd expe rienced music rat ers eva luate d th e perform an ce for va riou s t echnical points, one of whi ch wa s lack of tremor. When re cei ving ox pr eno lol, th e subjects had lowe r pulse a nd blood pressure, less nervousn ess, and improv em ent in m usical performan ce. T he a rea of g reates t improvem ent wit h th e drug was with t re mor. The subjects we re 110/ se lec t ed for nervou sn ess, a nd t hos e with a hist ory of ne rvou s o r m ent al illness were excluded . The oxpren olol wa s not ed to hav e a grea t er effec t befor e t he firs t perform an ce, sugges t ing th at sym p to ms may d ecr ease wit h t im e. A weakn ess of th is st udy was th at th e a u t ho rs did not inq uire as to specific ph ysical sym ptoms experie nced by th e subj ect s.
james a nd Savag e (3) co m pa re d th e effects of 40 m g nad olol and 2 mg d ia zep a m on st ring musicians in a placeb o-con troll ed s tudy. Na do lol was chose n fo r its hydrophilicit y a nd low lik elihood of e NS side effects . Subj ects wit h a h ist ory of nervous illn ess were exclud ed. The obse rve rs not ed th e subjects' specific ph ysical sig ns (t re mo r, swe a ting , flush ed ski n, talking a nd restl essness) ; t he subjects rat ed th emselves for palpitations, loss of conce n t ra t ion , gas t ro in test inal ups et , t re m bling, d etach ed feeling, and fr equ en cy of micturition, as well as a self-rating on th e qu ality of th eir performance. The nadolol g ro up was not ed to be pa ler than co n t rols. Four of 14 subjects had tremor with placeb o; all of th ese improved a ft e r nad olol. Nadolol was as sociat ed with a lower pulse and improvem ent in bowin g t echniqu e a nd in to na t ion. No differen ce wa s found in m ood st at es on a self-rat ing sca le wit h ac t ive drug. Diazepam was associat ed with a minor det erioration in pe rfo rm an ce.
Brantigan, Brantigan and j oseph (4) st ud ied in strumenta l mu sicia ns using pr opranolol and th e bet a-adren ergic a goni st terbut al ine. The subjects were eva luat ed for overall performance, nervou sn ess, a nd somat ic sym pto ms . T he pro pranolol group showed a signifi cant decr ea se in heart rat e, a n improve m en t in saliva producti on , a nd improvem ent in th e se lf-re po r ts of va rious ph ysical sym ptoms of perfo rmance anxi ety. The terbutaline, as pr edi ct ed incr ea sed th e symptom s. The subjects' sta te (but not trait) anxi et y decreased with propranolol. The resu lts of th e m usic rat ers' eva lua t ion of subjects' pe rformance in part of t heir st udy wa s sig nifica ntly better with propranolol.
Ne fte l, Ad ler, Kappcli e t a I. (30) st udied st ring players on a tenolol vs. pla cebo a nd found th e ac t ive dru g to d ecr ease various stage fri ght symptoms (on a sta gefri ght rating scale cons ist ing of two cog nitive qu estion s, two ph ysical questions and two technical/ m usical qu estion s) d uring t he pe rform ance bu t not im m ed ia t ely before it. As in o t he r st udies, t he act ive drug block ed t he during-pe rfor m a nce ta chycardia. Uri nary ca techo lamine m easurem ents were co ns iste n t with sympathoadrenal act ivation by st ress; th e a te no lol was felt to ac t by peripheral bloc kade of suc h activation a nd was associa te d with som e improvem ent in technical pe rfor m a nce. Th e main sym pa t he tic ac tiva t ion occ ur re d 90 sec o nds before th e begi nning of t he perform ance. A sho rtcom ing of t his st udy was th e rel a tive lack of scree ning fo r phys ical symptoms.
Gates, Saege rt , W ilson et a I. (5) st udie d singe rs with 20 mg, 40 mg, a nd 80 mg of nad olol a nd showed a limitati on of in traperform an ce hea r t rat e with all doses. The m usic j udges' ra tings for t he perform a nces sho wed a slight preference for performance with 20 m g nad olol vs. placeb o, while the high e r doses resul t ed in perform an ce judged as sig nifica n t ly poorer. This corre la te d to th e com me nts by some subjects th at t he high er doses decr eased th eir ene rgy . Th e a u t hors d id not report th e effec t of th e me d ica tion on specific sym ptoms .
Liden a nd G ottfri es (6) st ud ied instru m en tal musicians on e it he r 50 mg or 100 mg a lpre no lol vs. placeb o a nd fou nd a clear improve m ent in severity of se lf-re po rts in two sym p tom grou ps; palpit ation , incr eased m uscle to ne , a nd t remor were g ro upe d as th e "catecho la m ine synd ro me" while o t he r less specific symptoms (e.g., un easiness, irrit ability, a nd head ache) were g ro upe d as "ot her sym ptoms." No differen ce was found bet ween th e two do ses of a lpre no loI. No assessme n t of th e qu ality of m usical perfor mance o r obse rve r ratings of signs of anxie ty were reported.
J am es, Burgoyn e an d Savage (3 1) used pind olol on ins trumental musicians in a placeb o-controll ed st udy. The subjects' pu lse and blood pr essure were measured before th e performance . The subjects rat ed both t he ir level of a nxie ty and th ei r own pe rform an ce, a nd th e perform ance was eva luate d by a n expe rie nced professional musician. Th e pindolol g ro up showed signifi cantly lower pul se an d systolic blood pressure with th e ac tive dru g, a nd a lowe r a nx iety se lf-rat ing and higher performance ratings by t he ra te r in th e grou p of " bette r" pla ye rs. This study did not sp ecificall y ad dress th e various phys ica l sym ptoms of pe rfor m a nce anxiety.
Br ewer (32) st udied th e effect of ox prenolol vs. placebo on a "high anxi et y" grou p of universit y st ude n ts tak ing exa mi nations . H e started subj ects at 10 mg prop ranolol a nd incr eased doses until the subject's res ting pulse was slowed to 60 :± 5 BPM. H e co nclude d that th ere was a n improved perform an ce on exam inations by th ose wh o wo uld o the rwise be adverse ly a ffec te d by high levels of anxi ety, espec ia lly t hose st uden ts with promi nent ca rdio vascula r sympto ms .
T a ggart, Carru t he rs a nd Some rville ( 13) stud ied t he effec ts of 40 mg oxpren olol on su bjects speaking before an a ud ie nce . EKG mo nitori ng of a gro up of his subj ect s with coronary a r tery disease revealed ST d epression whe n t hose subjects spoke. T he ox pre nolol improved th es e EKG abno r malities a nd block ed t he anxiety-associat ed tach ycardia ; th eir st udy did not add ress th e ot her phys ica l sym ptoms or mental symptoms of perform an ce a nxie ty. Drew, Barnes a nd Evans (33) stu di ed t he effec ts of 120 m g propra nolol vs. placebo on st ude n t volun teers performing tests of verbal reas oning a nd m en tal a rit h me tic. The act ive drug group was shown to have im proved sco res in bot h perform an ce t ask s. U ndesirable effec ts were seen in nearly ha lf of th e subjects receiving propranolol; th e mo st fre q ue n t ly re port ed sym ptoms were nausea , headac he, a nd weak legs. The m aj or benefit of t reat m ent was seen in a subgro up who described th emselves as having a nxie ty sym pto ms . As on ly a sin gle do se was used in this st udy , it is not possibl e to d e termine whet her som e of th e cite d side effects were dose rel at ed.
Siitone n a nd Jan ne (34) st ud ied th e effec ts of 40 mg oxpre no lol on bowl ers in a placebo-controlled d esign. The oxpre no lol pr event ed pe rform an ce-r ela ted tach ycardi a a nd was associa te d with im proved bowling scores in a subgroup of subj ect s who had ex hi bite d a sig nifica n t ly high e r heart ra te before, d uring, a nd aft er th e co m pe t ition. This findin g is co nsis te n t wit h th e hypoth esis th at persons with subs tant ia l perform an ce a nxie ty sym p to ms m ay have a high er d egree of cardiovas cu lar reactivity to performance st res sors than other peopl e.
G orm an, Lieb owitz a nd Fyer e t a l. ( 12) st udied te n subj ects who met t he DSM-III criteria for soc ia l ph ob ia. The subjects all suffe red from variou s ph ysical com pla in ts in soc ia l se tt ings; of th ese sym p to ms , pal pit a tion s, sweating, and tremor were th e most com m only report ed. No effor t was mad e to separa te a performan ce a nxie ty subtyp e from gen eralized social phobia in this st udy, t ho ug h non e of th e te n had a hist o ry of spo n taneous panic a ttacks. Five of t he subjects had a hist ory of d epression , a nd five had a history of a lcoh ol a buse. Doses ranged from 50 mg to 100 m g a te no lol daily for th e six week s of th e trial. Ni ne of th e ten pati ent s in th is ope n, un controll ed st udy cite d " mode ra t e" or " mar ked" improvem en t in th eir socia l phobia symptoms. Sp ecific sym ptom improvem ent and ph ysiological measures were not addressed .
Lieb owit z, G orm an a nd Fye r e t a l. ( 11, 14) st udi ed 87 patients wh o m et th e DSM-III cr ite ria for socia l ph obi a in a ra ndom ized placebo-controlled trial of a te no lol a nd th e monoamine oxidase inhibitor ph enel zin e. Dail y a te no lol dos es were eit he r 50 or 100 mg (m ean, 95 mg) whil e dai ly ph enelzine do ses ra nged fro m 45-90 mg (m ean , 72 m g). Assessm ents included seve ral a nxie ty and depression inventories , plu s a soc ia l ph obi a scale, which included 12 di scr et e perfor m ance fears . Th ei r findin gs were that ph en el zin e was more effect ive for ge ne ralized soc ia l ph obia , wh ile at enolol was helpful for th e dis cr et e performance-rel at ed social ph obi a . A di fficulty with this st udy is th e lack of cle ar distinctions between th e ge ne ra lized versus performan ce-relat ed socia l phobia gro ups.
PHARMACOLOGICAL PROPERTIES OF T HE BETA-ADRE ERGIC BLOCKING AGENTS STUDIED
The ph armacolo gic properti es of th e beta-adren ergic blockin g ag e nts used in th e pr eviously di scus sed performance a nxie ty a nd soc ia l ph obi a st udies are summarized in T abl e 3. The cho ice of a specific bet a-adren ergic blocking agent fo r the treatment J EFFERSON J O URL'\lA L OF PSYCJ-lIATRY of t he phys ica l symptoms of perform an ce anxi ety depends substant ially o n two ph ar macological pr ope r ti es: lipid vs. H 20 so lubi lity and receptor se lect ivity. At en olol is a ca rdioselect ive (i.e ., beta-on e sel ective) , hydrophilic age n t (20, 27, 35, 36) . As a result, it s bet a-adren ergic actions a re more specific to th e heart a nd to blocking t ach ycardia. Because of it s hydrophilicit y, a t e no lol has rel a tively poor blood-brain barrier pen etration a nd thus less risk of th e CNS sid e effec ts occa sionally rep or t ed with more lipophil ic beta-adren ergic block ers suc h as pr op ran olol. T he finding in t he studies cite d ( 12, 30) that at eno lol ha s so me succes s in blo cking th e sym pt om s of pe rfo rmance anxi ety supports t he hypo t hesis that su ch sym p to ms a re medi a ted by a periphe ra l mechanism .
Propra nolol, by con tras t, is a nonsel ective a nd lip ophilic age n t. T he inciden ce of CNS sid e effec ts from bet a-adrenergic blockad e is report ed to be g rea te r with t he more lipoph ilic age nts , ye t is still infrequ ent , es pec ia lly a t clinica lly-a cce pt abl e doses (35) . Based on th e th erap eu t ic effec t of bet a-adren ergic blo cking ag ents on esse nt ia l tremor, it has been recomm ended that a nonselective a gent be used wh en tre mor is a significant target symptom (27, 36) .
Of th e other beta-adren ergic blocking age n ts cite d in th e above st udi es, only pindolol (moderately lipophilic and non selective ) and nad olol (hyd rophi lic a nd non sel ective) a re in co m m on use in th e U.S. As a ll of th e m ention ed bet a-ad re ne rgic blocking age n ts cite d showed at least so m e effec t in sympt o matic co nt ro l of performance anxiet y, and no psychiatric sid e effec ts were report ed in th e stu d ies , it wou ld Effect ive in 2 s t ud ies (12, 30) Effective in " D iscre te Socia l Phobia " Subgroup in 1 study ( 11, 14) see m a ppro pr iate to use a ny of t hem clinica lly. If t re mo r shou ld not be co nt ro lled with a te no lol, a change to a non sel ecti ve agent may be tried. Shou ld th e pati ent have a history of CNS side effec ts from a lip ophilic beta-adren ergic bloc ker, a switch to a less lipophilic ag ent cou ld be co ns ide re d .
OTHER PHARMACOLOGIC AND NON PHARMACO LOG IC T REATMENTS OF PERFORMANCE ANXIETY
When perform an ce a nxie ty is pr esent with t he ge ne ralize d type of social phobia, ph armacologic treatm ent with th e monoamine oxidase inhibi tor phene lzin e ca n be cons ide re d (14,20 ,21 ,37) . Do ses to co nside r range between 45 an d 90 mg daily. The usual ca u t ions a pply regarding co m plia nce with a tyr amine-free d iet and awaren ess of possibl e tyr amin e reaction.
For sympt oms of perform an ce a nx ie ty, ph arm acologic trea tment should includ e benzodiaz epin es onl y with great ca u tion. The risk of a lcohol ab use in t hese patients m ak es th e chance of benzodiazepine a buse sig nifica n t. If used for thi s purpose , benzodi a zepines sho uld be shor t half-life age n ts (e .g ., alprazo lam, lo ra ze pa m) a nd used prim arily on a limit ed , PRN ba sis.
Because of th e possible confus ion regarding panic di so rd e r vs. social phobia, it may be that som e pat ients presenting with perform an ce-r el at ed a nxiety symptoms a re in fa ct suffe re rs of primary panic disord er. If this is a clinica l possibility, the pati ent may respond better to tricyclic a n t ide pressan ts (22) .
For nonpharmacolo gic managem ent of perform an ce a nx ie ty sym ptoms, va rious int ervent ions have been recommend ed . Anxi et y m an a gem ent training involves exposure to th e phobic sit uat ions or a sim ila r sit ua t io n. An apt exam ple is Toastmaster's C lub for th ose with public speaking ph obi a ( 15, 37) . Rela xat ion training can be co m bine d with th e expos ure to th e phobic sit uat ion . The ex posure th e ra py may be most su ccessful wh en com bine d with cog nitive th erap y, wh erein th e th era pist helps th e patient to correct incorrect cog nit ions abo u t th e perceived co nsequences of his ph ysical sym pto ms, a nd to repl ace negative expec ta t ions wit h more hopeful ones regarding performance (37) .
Social skills tra ining can be cons ide re d for those patients wit h associa ted socia l dysfunction. This may require a g ro up form at a nd m ay incl ude assis tance in co m m u nica t ion a nd ass ertiveness. This m ay be particul arly va lua ble for the patient who m eet s th e crite ria for avoidant personality di sorder ( 15) .
Wha tev er approach is taken for patients with th e perform an ce a nx iety subtype of socia l ph obi a , pharmacologic treatm ent co m bine d wi th psych ologic in te rve n tion sho uld hav e as a co m mo n goal sym pto m reducti on , increased confi dence in good perform an ce, and cons olidate d, lon g-lasting improvem ent (7).
SUMMARY AND RECO MMENDAT IO NS
The evalu ation and managem ent of perform an ce a nx iety m ay challenge th e psych iatris t's diagnost ic, pharmacologic, m edi cal , a nd psych otherapeu tic skills. The patient who presents for help wit h disabling perform a nce anx iety sym pto ms, particularly t he mu sician, speake r, ac to r, or at hlete, m ay be fac ing a ca ree r-t hre a te ning pr obl em. The re is little marg in for erro r in perfor m ance for those who pursu e th ose ac tivities professionall y.
Careful history taking for th e ph ysical sym pto ms of perform a nce-rela ted sympath etic nervou s syste m discharge (t ach yca rdi a /palpitation s, sweating, and tremor bein g th e most co m monly m ention ed ), co nside ratio n of a diagnosis of panic disord er if suc h sym ptoms firs t a ppeared spon taneous ly and a re not a lways related to performance, a nd di fferentiation of lim ited social phobia from th e more global di sorders ge neralized soc ia l ph obi a an d avo idan t personality disord er are esse ntial. The psychi atrist mus t a lso rema in vigi la n t for concurrent depression, subs ta nce a buse / depe nde nce, and ot he r ph obi as t hat m ay be presen t in this population.
O nce havin g d etermined th at a pat ient does ind eed suffer from a limit ed soc ial ph obi a /performance a nx ie ty, th e clinicia n may cons ide r beta-adren ergic block er th erapy. One mu st be mindful of resting br ad ycardi a , di a betes m ellitus, rea ct ive airway di sease, Rayn aud's ph en om en on a nd ot he r m edi cal conditions which wou ld m ak e bet a-bl ock er th erap y problem atic. When bet a-block e r th e ra py is to be tried , th e clinicia n ca n sta r t at a low dose (e.g., proprano lol 20 mg to 40 mg or at enolol 50 mg) a nd tit rate up wa rd s to co nt ro l troubl esom e sym ptoms (38) . Th e patient should be taugh t to check his pul se a nd no t tak e high er doses if t he resting pu lse is less th an 60 BPM. Pulse a nd blood pressu re sho uld be checked on office visits. If th e patient has a history of CNS side effects from bet a-adren e rgic blockade (including th e ophthalmic pr ep a rat ion s of timolol, levobunolol, a nd be taxolol), th ese agents shou ld be used ve ry ca u tious ly.
For patients who face a sym p to mat ica lly ph obi c stim ulus on ly on occasion (e.g., th e mu sician who has a n occasional difficult a ud ition or per form an ce), th e use of bet a-adren e rgic blockad e on a PRN basis one or two hours pri or to performance may be ade q ua te . For th e limit ed social ph obi c who mu st face his ph obi c challenge and perform well dail y, dail y dosin g of th e me dica tion may be necessary. For th e athlet e who need s fine motor co n trol (e .g., the a rc he r, go lfer, or billiards pla yer ), t he cli nician mu st learn wh ethe r th e use of beta-blocke rs wo uld violate th e rules of t he sport's gove rn ing body. Bet a-adren ergic block ing agents are not among substan ces banned for Ol ympic a t hle te s (39) .
It may be mo st effec tive to com bine ph armacothera py with behavioral th erap y, cog n itive res t r uc t u ring a nd wh en need ed soc ial skills t ra in ing to ach ieve lasti ng results for this challe ng ing clinical pr obl em.
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